Caroline Seymour

Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer

Maintenance Tucatinib Plus HP Extends Median PFS Beyond 2 Years in Advanced HER2+ Breast Cancer

Loncastuximab Tesirine Plus Glofitamab Yields High CR Rates in DLBCL in Updated LOTIS-7 Analysis

FDA Approves Osvyrti and Jubereq in High Fracture Risk Populations, Including in Breast and Prostate Cancer

FDA Approves Daratumumab and Hyaluronidase-fihj in Newly Diagnosed Light Chain Amyloidosis

FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC

China’s Center for Drug Evaluation Grants Breakthrough Therapy Designation to Ivonescimab in TNBC

FDA Grants Breakthrough Therapy Designation to Zenocutuzumab in NRG1+ Cholangiocarcinoma

Cadonilimab Plus Chemo Retains Clinically Meaningful Survival Advantage in Frontline Gastric/GEJ Adenocarcinoma

Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC